COVID-19 Vaccines: EUA Route Offers Advantage In Review Speed, Not Level Of Evidence
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.
You may also be interested in...
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
In a JAMA article, senior FDA leaders state that the outside advisers will be needed to ensure transparency given the potentially widespread use of the vaccine.
With the company’s vaccine candidate in Phase III, Pfizer CEO Albert Bourla says there is pressure to perform because the hopes of the world are on the pharma industry to find a solution to the coronavirus pandemic.